{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","spread":"1.6","upperLimit":"12.5","value":"7.1"},{"groupId":"OG001","lowerLimit":"26.4","spread":"26.4","upperLimit":"46.1","value":"36.3"},{"groupId":"OG002","lowerLimit":"24.3","spread":"24.3","upperLimit":"43.8","value":"34.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Total symptom score is the averaged value of the daily scores for each of 6 key Myelofibrosis (MF) associated Symptom items (night sweats, pruritus, abdominal discomfort, early satiety \\[filling up quickly when you eat\\], pain under ribs on left side, and bone or muscle pain), each item measured on a scale from 0 (absent) to 10 (worst imaginable). A higher score indicates worse symptoms. Analysis was performed on ITT population. Number of participants analysed= participants with available data at end of cycle 6.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo up to 6 cycles (1 cycle=28 days - median exposure= 24 weeks). At the end of cycle 6, participants were crossed-over to SAR302503 400 or 500 mg until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo"},{"description":"SAR302503 400 mg until disease progression and/or unacceptable toxicity (median exposure= 62.1 weeks).","id":"OG001","title":"SAR302503 400 mg"},{"description":"SAR302503 500 mg until disease progression and/or unacceptable toxicity (median exposure =59.7 weeks).","id":"OG002","title":"SAR302503 500 mg"}],"paramType":"NUMBER","populationDescription":"All treated participants with available data at baseline and the end of cycle 6.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 24","title":"Symptom Response Rate (SRR): Percentage of Participants With >=50% Reduction From Baseline in the Total Symptom Score at End of Cycle 6","type":"SECONDARY","unitOfMeasure":"percentage of participants"}